Case Report

Huge mesenteric desmoid-type fibromatosis with unusual presentation: A case report

Mohamed Hajri a, c, Ghofrane Talbi a, c, Wael Ferjaoui a, c, * Aziz Atallah a, c, Sana Ben Slama b, c, Hafedh Mestiri a, c, Rached Bayar a, c

a Department of General Surgery, Mongi Slim University Hospital, Tunis, Tunisia
b Department of Pathology, Mongi Slim University Hospital, Tunis, Tunisia
c Faculty of Medicine of Tunis, Tunis El Manar University, Tunis, Tunisia

ARTICLE INFO

Keywords:
Desmoid tumors
Fibromatosis
Peritonitis

ABSTRACT

Introduction: Desmoid-type fibromatosis, also known as desmoid tumors, are rare fibroblastic neoplasms that account for less than 3% of all soft tissue tumors. Although they are benign neoplasms without metastatic potential, they are known to be locally aggressive and may invade adjacent structures leading to fatal complications.

Case presentation: We describe the case of a 26-year-old woman who presenting with the clinical picture of acute peritonitis. Emergency surgery was performed and a large poorly-circumscribed heterogeneous tumor was found, occupying the jejunal mesentery and infiltrating the jejunal wall causing its perforation into the abdominal cavity. En bloc resection of the tumor and the involved jejunum was performed. Histology and immunohistochemistry confirmed it to be mesenteric desmoid-type fibromatosis. The postoperative course was uneventful and the patient had no evidence of recurrence 18 months after tumor resection.

Conclusions: Mesenteric desmoid-type fibromatosis is a rare condition with insidious growth and locally aggressive behavior. Serious complications such as bowel perforation are rare but possible, as shown in our presentation. Complete surgical resection is the first-line treatment but high recurrence rates remain problematic.

1. Introduction

Desmoid tumors, also known as fibromatosis, are benign fibroblastic neoplasms that account for less than 3% of all soft tissue tumors [1]. The most occurring locations are the limbs, the abdominal wall and rarely the abdominal cavity, particularly the mesentery. They can occur sporadically or in the context of congenital syndromes such as familial adenomatous polyposis (FAP) [2]. Although desmoid tumors are benign neoplasms without metastatic potential, they are known to be locally aggressive and may invade adjacent structures leading to fatal complications [3]. We report hereby a rare case of a mesenteric desmoid-type fibromatosis presenting with intestinal perforation and acute diffuse peritonitis.

This case follows 2020 SCARE guidelines for reporting of cases in surgery [4].

2. Case presentation

A 26-year-old woman presented to the emergency department with a 24-h history of increasing abdominal pain with nausea and vomiting. Her past medical history was unremarkable and there was no notable family history. She had no Drug History and Allergies. She reported a change in bowel habits since 3 months.

Clinically, she was awake and conscious, with a temperature at 37.4 °C, blood pressure at 11/06 cmHg, heart rate at 110/min and respiratory rate of 18 breaths/min.

Abdominal examination revealed diffuse tenderness with a mobile mass on palpation in the mid-abdomen.

Laboratory studies showed a normal white blood cell count of 5.77 × 10^9/L (normal range, 3.50–9.50 × 10^9/L), elevated blood levels for C-reactive protein (203 mg/L; normal range, 0–10 mg/L) and normal kidney and liver tests.

Computed tomography (CT) demonstrated a 23 × 11 × 10 cm intra-...
abdominal mass with small intestine compression and free intraperitoneal air and ascites (Fig. 1).

Emergency surgery was performed by an associate professor in general surgery, under general anesthesia with the patient in dorsal decubitus position. Intraoperatively, a large poorly-circumscribed heterogeneous tumor was found, occupying the jejunal mesentry and infiltrating the jejunal wall (Fig. 2) causing its perforation into the abdominal cavity. The above imaging and intraoperative findings suggested a GIST invading the small bowel. En bloc resection of the tumor with a 30 cm segment of the small bowel was performed and a double-barrel ileostomy was carried out. The postoperative course was uneventful.

Gross examination showed a solid mass poorly-circumscribed, firm, whorled and white cut surface (Fig. 3).

Histological examination showed fibroblastic and myofibroblastic proliferation with many bundles of spindle-shaped cells. In immunohistochemistry, it was positive for B-catenin, Desmin and SMA, and negative for CD117, CD34 and S100 protein (Fig. 4), supporting the diagnosis of desmoid-type fibromatosis.

Since postoperative total colonoscopy found no polyposis, the tumor was considered to be sporadic.

She recovered well and restoration of bowel continuity was performed two months after surgery. She had no evidence of recurrence 18 months after tumor resection.

3. Discussion

Desmoid-type fibromatosis (DF), also known as desmoid tumors or aggressive fibromatosis, are monoclonal fibroblastic proliferations arising in musculoaponeurotic structures [5].

They are reported to account for less than 3% of all soft tissue tumors and less than 0.03% of all neoplasms [6].

Although DF are benign neoplasms with no potential for metastasis or dedifferentiation, they exhibit a locally aggressive infiltrative behavior [5].

It can present sporadically or as a part of congenital syndromes such as FAP or Gardner’s syndrome. Thus, colonoscopy is recommended in DF patients in order to detect polyps [7].

Female gender, estrogen exposure, previous abdominal surgery and trauma have been found to be associated with the occurrence of these tumors [8,9].

Our patient have not experienced prior surgery or trauma, and total colonoscopy did not detect polyposis, thus DF was considered to be sporadic.

While intra-abdominal site is very common in FAP-related cases, it is very rare in sporadic setting, accounting for less than 5%–10% of cases, and the mesentery is the most occurring intra-abdominal location [10].

The diagnosis of mesenteric desmoid-type fibromatosis (MDF) is usually delayed due to its insidious development as well as its nonspecific clinical signs [11].

Given the locally aggressiveness of the disease, this can lead to several life-threatening complications caused by adjacent tissues invasion including bowel obstructions, perforations, and ischaemia [12].

We reported a rare case of diffuse peritonitis due to sporadic MDF with aggressive proliferation and consecutive intestinal perforation. Only a few similar cases have been reported in the literature [12] [13].

A recent Italian study reported 72 patients treated at Istituto Nazionale dei Tumori (INT) in Milano from 2005 to 2020 for intra-abdominal DF. Among these patients, only 5 presented with bowel perforation. The DF was of mesenteric origin in all 5 cases [12].

Differential diagnoses of MF include essentially GISTs, fibrosarcomas, lymphomas and carcinoid tumors.

MDF may occasionally mimic GISTs arising from the mesentery or peritoneum because of their morphological similarities [16,17]. Differentiating MDF from GISTs is important due to the differences in treatment [16,18].

Histologically, both DF and GISTs are characterized by a proliferation of spindle-shaped cells, so differentiation using routine hematoxylin and eosin staining is difficult. However, distinction between these tumors is based on immunohistochemical and molecular analytical techniques. While GISTs are known to show positive stainings for CD117, CD34, DOG 1 and PDGFRA, DF are characterized by positive beta-catenin expression and lack of CD34 expression. Hence, staining for beta-catenin and CD34 is recommended whenever there is diagnostic doubt between MF and GISTs [16].

Surgery is the mainstay treatment for MDF, and complete surgical resection is recommended when technically feasible. However, despite complete resection with negative microscopic margins, local recurrence rate is high and may be to 40%–70% [19]. Associated congenital syndromes such as FAP or Gardner’s syndrome are seen to be risk factors of recurrence [20,21]. It has been reported that DF recurs in 90% of patients with FAP and 11% of patients without FAP [22].

Besides surgery, the DF management involves multiple other approaches. Radiotherapy can play a role in unresectable cases, recurrent tumors or after incomplete resection.

Janssen et al. reported a meta-analysis including 1295 patients treated for DF. Adjuvant radiotherapy appeared to reduce the risk of recurrence after incomplete surgical resection, particularly in patients with recurrent tumors. However, it had no detectable benefit on recurrence after complete surgical resection with negative margins [23]. In a systematic review reported by Seinen et al., adjuvant radiotherapy with a combined dose of ≥50 Gy showed a significant advantage over surgery alone [24]. Nevertheless, the use of radiotherapy for the intra-abdominal DF is limited because of its bowel toxicity and consecutive enteritis.

Some systematic treatment options such as non-steroidal anti-inflammatory drugs, tyrosine kinase inhibitors, cytotoxic chemotherapy (vinblastine, doxorubicin) and anti-hormonal therapies have been reported to be effective [25,26]. However, additional studies are needed to develop the optimal strategy for DF treatment.

In our case, we managed an emergent case of intestinal perforation due to huge infiltrative MDF. Emergency surgery was inevitable and complete resection of the tumor and a 30 cm of the small bowel was performed. Histology showed negative margins and no adjuvant therapy.
was carried out. Although the patient had no evidence of recurrence 18 months after surgery, further follow-up is mandatory.

4. Conclusion

MDF is a rare condition with insidious growth and locally aggressive behavior. Serious complications such as bowel perforation are rare but possible, as shown in our presentation. Complete surgical resection is the first-line treatment but high recurrence rates remain problematic. Multidisciplinary care is always necessary and further studies and clinical trials are required to establish structured guidelines.

Patient perspective

The procedure of surgery was explained to the patient with all advantages and possible complications. He agreed on the procedure and informed consent was taken from her.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

Ethics approval

Not applicable.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author’s contribution

Mohamed Hajri, Ghofrane Talbi, Wael Ferjaoui: Writing, review and editing of the manuscript.
Aziz Atallah, Sana Ben Slama: Contributed for diagnosis and treatment of the patient.
Hafedh Mestiri, Rached Bayar: Review, Supervision and surgeons of the patient.

Registration of research studies

1 Name of the registry:
2 Unique identifying number or registration ID:
3 Hyperlink to your specific registration (must be publicly accessible and will be checked):

Guarantor

Wael Ferjaoui.

Provenance and peer review

Not commissioned, externally peer reviewed.
Annals of Medicine and Surgery 78 (2022) 103741

Fig. 4. Microscopic examination showing proliferation of long sweeping fibroblasts and myofibroblasts (hematoxylin-eosin: HEx100). Cartridge: Cells demonstrate eosinophilic cytoplasm without cytologic atypia, blood vessels with perivascular oedema (hematoxylin-eosin: HEx200).

Declaration of competing interest

The authors declared no potential conflicts of interests with respect to research, authorship and/or publication of the article.

References

[1] O. Micke, M.H. Seegenschmiedt, German cooperative group on radiotherapy for benign diseases. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study, Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 882–911.

[2] S. Weiss, J. Gouldblum, Benign lipomatous tumors, in: F.M. Enzinger, S.W. Weiss (Eds.), Soft Tissue Tumors, third ed., St Louis Mosby, 1995, pp. 381–430.

[3] C. Shields, D. Winter, W. Kirwan, et al., Desmoid tumours, Eur. J. Surg. Oncol. 27 (2001) 701–706.

[4] R.A. Agha, T. Franchi, C. Sohrabi, G. Mathew, for the SCARE Group, The SCARE 2020 guideline: updating consensus surgical Case REport (SCARE) guidelines, Int. J. Surg. 84 (2020) 226–230.

[5] V.Y. Jo, C.D. Fletcher, WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition, Pathology 46 (2014) 95–104.

[6] D.P. Mishra, S.S. Rout, Desmoid tumors: a clear perspective or a persisting enigma? A case report and review of literature, World J. Oncol. 7 (2016) 21.

[7] A. Al-Nafussi, N. Wong, Intra-abdominal spindle cell lesions: a review and practical aids to diagnosis, Histopathology 38 (2001) 387–402.

[8] A. Sinha, P. Tekkis, D.C. Gibbons, et al., Risk factors predicting desmoid occurrence – a systematic review of clinical subgroups, Int. J. Radiat. Oncol. Biol. Phys. 61 (2005) 891–901.

[9] M.H. Nieuwenhuis, M. Casparie, L.M. Mathus-Vliegen, et al., A nation-wide study on the 2013 (4th) edition, Pathology 46 (2014) 95–104.

[10] B. Kasper, C. Baumgarten, J. Garcia, et al., An update on the management of aggressive fibromatosis: experience from a single institution, Radiat. Oncol. 15 (2020) 1–9.

[11] Y. Asenov, S. Genadiev, A. Timev, et al., Ruptured desmoid tumor imitating acute appendicitis—a rare reason for an emergency surgery, BMC Surg. 19 (2019) 1–5.

[12] F. Fini, M. Fiore, S. Provenzano, et al., Management of serious complications in intra-abdominal desmoid-type fibromatosis, Cancer Rep. (2021) e1411.

[13] Li J, Xu R, Hu D-M. Rare Acute Abdominal Condition Caused by Desmeeen Fibromatosis Perforation: a Case Report. Medicine (Baltimore); 98.

[14] M. Tawada, Y. Misao, T. Sugimoto, et al., Ruptured mesenteric desmoid-type fibromatosis without emergency surgery: a rare case report, Int. J. Surg. Case Rep. 85 (2021) 106208.

[15] Y. Xu, Z. Duan, W. Hu, et al., Huge mesenteric fibromatosis presenting with intestinal perforation and acute diffuse peritonitis: a case report, Transl. Cancer Res. 9 (2020) 5674–5678.

[16] N. Ogawa, H. Iseki, H. Tsunozaki, et al., An intra-abdominal desmoid tumor difficult to distinguish from a gastrointestinal stromal tumor: report of two cases, Surg. Today 44 (2014) 2174–2179.

[17] J.G. van Roggen, M. Van Veldhuizen, P. Hogendoorn, The histopathological differential diagnosis of gastrointestinal stromal tumours, J. Clin. Pathol. 54 (2001) 96–102.

[18] J. Church, C. Lynch, P. Neary, et al., A desmoid tumor-staging system separates patients with intra-abdominal, familial adenomatous polyposis-associated desmoid disease by behavior and prognosis, Dis. Colon Rectum 51 (2008) 897–901.

[19] J. Khorasand, C.P. Karakousis, Desmoid tumors and their management, Am. J. Surg. 149 (1985) 215–218.

[20] A.P. Burke, L.H. Sobin, K.M. Shrikita, et al., Intra-abdominal fibromatosis. A pathologic analysis of 130 tumors with comparison of clinical subgroups, Am. J. Surg. Pathol. 14 (1990) 335–341.

[21] S.A. Al Jadaan, A. Al Rabeeah, Mesenteric desmoid fibromatosis: case report and literature review, J. Pediatr. Surg. 34 (1999) 1130–1132.

[22] K. Seidennaal, S. Harrabi, F. Weykamp, et al., Radiotherapy in the treatment of aggressive fibromatosis: experience from a single institution, Radiat. Oncol. 15 (2020) 1–9.

[23] M. Janssen, D. Van Broekhoven, J. Cates, et al., Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis, J. Br. Surg. 104 (2017) 347–357.

[24] J.M. Seinen, M.G. Niebling, E. Bastiaannet, et al., Four different treatment options for advanced disease, Oncol. 16 (2011) 682.

[25] K. Seidenwaal, S. Harrabi, F. Weykamp, et al., Radiotherapy in the treatment of aggressive fibromatosis: a European consensus initiative between sarcoma patients EuroNet (SPAEN) and European organization for research and treatment of cancer (EORTC)/Soft tissue and bone sarcoma group (STBSG), Ann. Oncol. 28 (2017) 2399–2408.

[26] X. Yao, T. Corbett, A. Gupta, et al., A systematic review of active treatment options in patients with desmoid tumours, Curr. Oncol. 21 (2014) 613–629.